Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 15, 2009

Chilean Firm CeTeCancer to Evaluate Radient’s Lung Cancer IVD for Clinical Applications

  • CeTeCancer, a Chilean-based research laboratory, has agreed to validate Radient Pharmaceuticals’ Onko-Sure™ in vitro diagnostic (IVD) as a tool for the early detection and prevention of lung cancer. CeTeCancer will provide clinical samples and perform all clinical testing.

    The project is supported by Innova Corfo and will run for 18 months. Final results are anticipated to be published in early 2011.

    Onko-Sure is a noninvasive blood test that is designed for the detection and/or monitoring of 14 different types of cancer including lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, and pancreatic. It is sold as a blood test for cancer in Europe, India, Taiwan, Korea, and Vietnam as well as for research use in Chile.

    It also has FDA clearance for the monitoring of colorectal cancer. Additionally, the test is approved in Canada for lung cancer detection and lung cancer treatment monitoring.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »